Bupivacaine ER is a Small Molecule owned by Pacira BioSciences, and is involved in 77 clinical trials, of which 66 were completed, 8 are ongoing, and 3 are planned.

Bupivacaine is an amide-type, long-acting local anesthetic. Bupivicaine reversibly binds to specific sodium ion channels (1,2,3,4,5,8,9,10, 11) in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.

The revenue for Bupivacaine ER is expected to reach a total of $16.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bupivacaine ER NPV Report.

Bupivacaine ER is currently owned by Pacira BioSciences.

Bupivacaine ER Overview

Bupivacaine (Exparel) is an amide-type local anesthetic agent. It is formulated as liposomal extended release suspension for infiltration route of administration. Exparel is indicated for single-dose infiltration in patients 6 years of age and older to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Exparel is developed based on DepoFoam platform which is a multivesicular liposomal platform that encapsulates drugs without altering their molecular structure and release the drug over an extended period of time by erosion and/or reorganization of the particles lipid membranes. Bupivacaine is under development for the treatment of upper and lower extremity nerve blocks for patients undergoing total knee arthroplasty and brachial plexus nerve block for patients undergoing either total shoulder arthroplasty or rotator cuff repair and postoperative pain in Hallux valgus (Bunion). It is administered through intrathecal route. It was also under development for the treatment of chronic lower back pain and dupuytren contracture.

Pacira BioSciences Overview

Pacira BioSciences (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, and relieve pain and symptoms related to osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. The company sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Tampa, Florida, the US.

The company reported revenues of (US Dollars) US$541.5 million for the fiscal year ended December 2021 (FY2021), an increase of 26% over FY2020. In FY2021, the company’s operating margin was 16.6%, compared to an operating margin of 8.9% in FY2020. In FY2021, the company recorded a net margin of 7.8%, compared to a net margin of 33.9% in FY2020. The company reported revenues of US$167.5 million for the third quarter ended September 2022, a decrease of 1.1% over the previous quarter.

Quick View – Bupivacaine ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Bupivacaine ER
Administration Pathway
  • Infiltration
  • Intrathecal
Therapeutic Areas
  • Central Nervous System
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.